Testosterone Therapy for Women: What the Research Actually Says

This guide was written in alignment with Dr. Rachel Rubin, MD, a board-certified urologist and sexual medicine specialist, faculty member at the Harvard Medical School CME on Testosterone and Sexual Health, and one of the leading clinical voices on women's hormone health in the United States.

Introduction: A Treatment Most Women Don't Know Exists

Most women have never heard of testosterone therapy. When they think of hormone therapy during menopause, estrogen and progesterone come to mind — not testosterone.

This is a significant gap in medical knowledge, both among patients and many healthcare providers.

"Most primary care doctors don't ask about sexual function. Patients don't know to bring it up, and providers don't bring it up either."

— Dr. Rachel Rubin, MD, board-certified urologist and sexual medicine specialist

The result: millions of women suffering from symptoms that testosterone therapy could meaningfully improve — and never being offered the treatment.

This post is a guide to what the evidence actually says about testosterone therapy for women, based on what the leading clinicians and medical societies recommend, with direct citations so you can verify every claim yourself.

Section 1: What Is Testosterone Therapy for Women?

Testosterone is often framed as a male hormone. But women's bodies produce testosterone too — in the ovaries, adrenal glands, and peripheral tissues. Testosterone plays a meaningful role in women's energy, libido, bone density, muscle mass, and cognitive function.

Women's testosterone levels peak in their 20s and decline steadily through perimenopause and menopause. By menopause, many women's testosterone levels are less than half of what they were at their peak.

Testosterone therapy for women is the use of exogenous testosterone to treat low testosterone levels and associated symptoms. It is not the same as male TRT — the doses are substantially lower, the goals are different, and the delivery methods are tailored to women's physiology.

What It Is Not

Testosterone therapy for women is not:

• A "performance enhancement" treatment
• The same as anabolic steroid use
• A treatment that causes virilization when used at physiologic doses

The fear of virilization is one of the most common reasons doctors hesitate to prescribe testosterone to women. The evidence consistently shows this fear is not grounded in clinical reality at physiologic replacement doses.

Section 2: What Does the Evidence Actually Say?

NAMS 2022 Position Statement

The North American Menopause Society (NAMS) issued its most recent Position Statement on testosterone therapy for women in 2022. The key conclusions:

"The evidence supports testosterone therapy for postmenopausal women with HSDD — Hypoactive Sexual Desire Disorder — who have been properly diagnosed."

— NAMS Position Statement on Hormone Therapy and Health Risks, Menopause, 2022

NAMS recommends against routine use of testosterone for women without a diagnosis of HSDD or androgen deficiency. But for women with diagnosed HSDD or clinically low testosterone, the evidence for benefit is favorable.

The Endocrine Society Guidelines

The Endocrine Society's clinical practice guidelines recommend testosterone therapy for women with HSDD, citing evidence that transdermal testosterone improves sexual function, including desire, arousal, and satisfaction.

Sources: NAMS Position Statement 2022, Menopause (menus.org) · Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology & Metabolism, 2020

What the RCT Evidence Shows

Multiple randomized controlled trials (RCTs) have examined testosterone therapy in women. Key findings:

Sexual function: Davis, et al. (2008) — a landmark RCT published in the New England Journal of Medicine — found that transdermal testosterone therapy significantly improved sexual function in postmenopausal women with HSDD, including increases in desire, arousal, and frequency of satisfying sexual events.

No virilization at physiologic doses: Glaser, et al. published a systematic review in Maturitas (2013, updated 2021) confirming that testosterone therapy at physiologic replacement doses in women does not cause virilization. The authors noted: "The risk of androgenic side effects is minimal at recommended doses."

Bone density: Some evidence supports testosterone's role in maintaining bone density in postmenopausal women, though this is less studied than the sexual health applications.

Energy and well-being: Several studies have found improvements in energy, vitality, and sense of well-being, though these effects are less consistent across trials than the sexual health benefits.

Section 3: HSDD — The Condition No One Talks About

Hypoactive Sexual Desire Disorder (HSDD) is a persistent or recurrently reduced sexual interest or desire, causing clinically significant distress.

HSDD affects an estimated 40% of postmenopausal women, making it one of the most common female sexual disorders — and one of the least discussed.

"HSDD is not 'just getting older.' It's a medical condition with a diagnosis and a treatment. And testosterone therapy, particularly transdermal testosterone, is the evidence-based first-line treatment."

— Dr. Rachel Rubin, MD

The key diagnostic criteria for HSDD: persistently or recurrently reduced sexual interest or desire; the symptoms cause clinically significant distress; and the symptoms are not better explained by another condition, medication, or relationship problem.

The condition is underdiagnosed because: doctors don't routinely screen for it; patients don't know it's a treatable medical condition; and there's still stigma around discussing sexual health openly.

Source: ISSWSH Clinical Practice Guideline for Testosterone Use in Women, Journal of Sexual Medicine, 2021

Section 4: What Does Testosterone Therapy Look Like for Women?

Form and Dosing

The most commonly used forms of testosterone therapy for women are:

Transdermal (preferred): Testosterone cream or gel applied to the skin. Allows for precise, low-dose delivery. Avoids first-pass liver metabolism. Preferred because it maintains more stable testosterone levels.

Oral: Lower doses than used in men. Less commonly used due to variable absorption.

Pellets: Subcutaneous testosterone pellets providing sustained release over several months. Requires in-office procedure. Dr. Rubin has noted concerns about titrating doses with pellets — once inserted, they cannot be easily adjusted.

Compounded preparations: Many women's hormone practices use compounded testosterone creams tailored to the individual patient. Not FDA-approved but widely used in integrative and hormone specialty practices.

Typical physiologic replacement dose for women: approximately 0.5–1 mg/day (transdermal) — substantially lower than male dosing, which typically starts at 50–100 mg/week.

What It Does NOT Look Like

Testosterone therapy for women at physiologic replacement doses does NOT: cause voice deepening, cause male-pattern hair growth (at physiologic doses), increase muscle mass to male levels, or create aggressive behavior.

These are androgenic effects associated with supraphysiologic (above-normal) testosterone levels — not the low-dose physiologic replacement used in evidence-based women's hormone care.

Monitoring

Recommended monitoring for women on testosterone therapy:

• Baseline: Total testosterone, free testosterone, SHBG, estradiol, CBC, lipid panel, liver function
• 3 months: Repeat testosterone levels to assess for supraphysiologic levels
• 6 months: Reassess symptoms and labs
• Annually: Full hormone panel and metabolic monitoring

The target is to restore testosterone to the physiologic normal range for women — not to supraphysiologic levels.

Section 5: Who Should Consider Testosterone Therapy?

You may be a candidate for testosterone therapy if you are:

• A postmenopausal woman experiencing reduced libido causing distress
• A perimenopausal woman with symptoms of androgen deficiency
• A woman with confirmed low testosterone levels (diagnosed via lab work)
• A woman who has been evaluated by a provider who specializes in sexual medicine or hormone therapy

You should NOT consider testosterone therapy if you: are pregnant or may become pregnant; have a hormone-sensitive cancer; have uncontrolled cardiovascular disease; or have not been evaluated by a qualified healthcare provider.

Section 6: What to Ask Your Provider

If you're interested in testosterone therapy, Dr. Rachel Rubin's framework recommends asking these questions at your appointment:

1. "Do you offer testosterone therapy for women?" — Not all providers are comfortable prescribing off-label testosterone for women. Find one who is.
2. "What form do you prescribe and why?" — Transdermal (cream or gel) is generally preferred over oral or pellet for titratability.
3. "What baseline labs do you run before prescribing?" — A thorough workup should include total T, free T, SHBG, estradiol, CBC, and metabolic panel.
4. "How do you monitor for side effects?" — You should have follow-up labs within 3 months of starting therapy.
5. "What's your approach if I don't respond to the first protocol?" — Testosterone therapy often requires dose adjustment. A good provider will iterate.
6. "Do you offer women's testosterone therapy, or do you only treat men?" — Many TRT clinics focus exclusively on men. TRTfinder's Women's Hormone Finder specifically identifies clinics that offer women's testosterone therapy.

Section 7: TRTfinder — Find a Provider Who Understands Women's Hormone Health

One of the challenges women face in accessing testosterone therapy is finding a provider who understands it and offers it.

Most general practitioners are not trained in sexual medicine. Many TRT clinics focus exclusively on men. And OB/GYNs, while often knowledgeable about estrogen and progesterone, may be less familiar with testosterone therapy for women.

TRTfinder.com was built specifically to solve this problem. Our Women's Hormone Finder:

• Verifies every listed provider's services — including whether they offer testosterone therapy for women
• Highlights providers with the Women's T-Th badge — indicating they offer hormone therapy for women including testosterone
• Allows filtering by location, telemedicine availability, and specialty
• Is free to search — the directory exists to connect patients with the right providers

Conclusion: The Evidence Is Clear. Why Aren't More Women Getting This Treatment?

The evidence supporting testosterone therapy for women with HSDD and androgen deficiency is strong, consistent, and endorsed by the leading medical societies in women's health.

The barriers are not scientific. They're practical: lack of provider knowledge, lack of patient awareness, stigma around discussing sexual health, and a healthcare system that doesn't routinely screen for these conditions.

"Most women don't know to ask," says Dr. Rubin. "And most providers don't bring it up."

That's the gap TRTfinder.com is working to close — by making it easier to find a provider who takes women's hormone health seriously.

If you're a woman experiencing reduced libido, fatigue, brain fog, or other symptoms that have affected your quality of life — and haven't found answers — this may be the question worth asking.

"Do you offer testosterone therapy for women?"— The question to ask your provider